Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

[1]  Ahmed M. Gad,et al.  Linear Mixed Models for Longitudinal Data with Nonrandom Dropouts , 2006, Journal of Data Science.

[2]  A. Nederveen,et al.  Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned , 2014, Journal of Inherited Metabolic Disease.

[3]  D. Zahrieh,et al.  Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up. , 2014, Blood cells, molecules & diseases.

[4]  D. Rosenthal,et al.  Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat , 2014, Skeletal Radiology.

[5]  C. Hollak,et al.  Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. , 2013, Blood cells, molecules & diseases.

[6]  F. Sedel,et al.  The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients , 2012, Orphanet Journal of Rare Diseases.

[7]  D Gianola,et al.  Technical note: an R package for fitting generalized linear mixed models in animal breeding. , 2010, Journal of animal science.

[8]  G. Grabowski.  Phenotype, diagnosis, and treatment of Gaucher's disease , 2008, The Lancet.

[9]  C. Hollak,et al.  Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy , 2008, Haematologica.

[10]  A. Haims,et al.  Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. , 2008, AJR. American journal of roentgenology.

[11]  P. Kaplan,et al.  Prevalence of type 1 Gaucher disease in the United States. , 2008, Archives of internal medicine.

[12]  J. Goldblatt,et al.  Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. , 2007, AJR. American journal of roentgenology.

[13]  P. Alfonso,et al.  S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease. , 2007, European journal of radiology.

[14]  R. Brady,et al.  Enzyme replacement and gene therapy for Gaucher's disease , 1996, Lipids.

[15]  K. Lutsky,et al.  Orthopaedic manifestations of Gaucher disease. , 2007, Bulletin of the NYU hospital for joint diseases.

[16]  P. Meikle,et al.  Epidemiology of lysosomal storage diseases: an overview , 2006 .

[17]  K. Sims,et al.  Quality of life assessment in adults with type 1 Gaucher disease , 1999, Quality of Life Research.

[18]  G. D. den Heeten,et al.  Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience. , 2003, Radiology.

[19]  B. Bembi,et al.  Response of Gaucher bone disease to enzyme replacement therapy. , 2002, The British journal of radiology.

[20]  L. Poll,et al.  Imaging and quantifying skeletal involvement in Gaucher disease. , 2002, The British journal of radiology.

[21]  C. Hollak,et al.  Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. , 2001, Blood cells, molecules & diseases.

[22]  D. Häussinger,et al.  Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results , 2001, Skeletal Radiology.

[23]  R. O'Donnell,et al.  Pseudo-osteomyelitic crisis upon presentation of Gaucher disease , 2001, Skeletal Radiology.

[24]  P. Kaplan,et al.  The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.

[25]  G. Pastores,et al.  Bone and joint complications related to Gaucher disease , 2000, Current rheumatology reports.

[26]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[27]  G. Hermann,et al.  Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement , 1997, Skeletal Radiology.

[28]  R. Longo,et al.  Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy , 1997, European Radiology.

[29]  P. Colletti,et al.  MR imaging of patients with type 1 Gaucher's disease: relationship between bone and visceral changes. , 1995, AJR. American journal of roentgenology.

[30]  R. Mcpherson,et al.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population. , 1993, American journal of human genetics.

[31]  J. Dambrosia,et al.  Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. , 1992, Radiology.

[32]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[33]  M. Clouse,et al.  Gaucher disease: assessment with MR imaging. , 1986, Radiology.

[34]  J. Scott,et al.  Evaluation of Gaucher disease using magnetic resonance imaging. , 1986, The Journal of bone and joint surgery. American volume.

[35]  R. Brady,et al.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. , 1966, The Journal of clinical investigation.

[36]  M. Makin,et al.  Aseptic osteomyelitis in Gaucher's disease. , 1965, Israel journal of medical sciences.